Publications by authors named "Christopher Missling"

Claim this Profile
T
The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome.
Ene I Ette, Emmanuel O Fadiran, Christopher Missling, Edward Hammond

Br J Clin Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
Stephen Macfarlane, Timo Grimmer, Ken Teo, Terence J O'Brien, Michael Woodward, Christopher U Missling

J Prev Alzheimers Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of illness in Rett syndrome: initial evaluation of a disorder-specific caregiver survey.
Walter E Kaufmann, Alan K Percy, Jeffrey L Neul, Jenny Downs, Helen Leonard, Christopher U Missling

Orphanet J Rare Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease.
Emmanuel O Fadiran, Edward Hammond, James Tran, Christopher U Missling, Ene Ette

Clin Pharmacol Drug Dev· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QTc Relationship from a Single Ascending Dose Study of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease.
Emmanuel O Fadiran, Edward Hammond, James Tran, Hongqi Xue, Janell Chen, Christopher U Missling

Clin Pharmacol Drug Dev· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain cell signaling abnormalities are detected in blood in a murine model of Fragile X syndrome and corrected by Sigma-1 receptor agonist Blarcamesine.
Patricia Cogram, Robert M J Deacon, Daniel Klamer, Nell Rebowe, Jeffrey Sprouse, Christopher U Missling

Am J Med Genet A· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy.
Samantha T Reyes, Robert M J Deacon, Scarlett G Guo, Francisco J Altimiras, Jessa B Castillo, Christopher U Missling

Sci Rep· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.
Harald Hampel, Coralie Williams, Adrien Etcheto, Federico Goodsaid, Frédéric Parmentier, Christopher U Missling

Alzheimers Dement (N Y)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome.
Walter E Kaufmann, Jeffrey Sprouse, Nell Rebowe, Taleen Hanania, Daniel Klamer, Christopher U Missling

Pharmacol Biochem Behav· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis